(pdf)

FDA user fee reauthorization law expands fees to include generic and biosimilar applications, and includes a new emphasis on drug supply chain safety and incentives for development of new therapies.

Initial guidance provides insights on regulatory pathway for biosimilars, but does not address many critical issues.